Investigation of the synergistic effect of selenium nanoparticles and metformin on ovarian tissue, oocyte quality, and maturity in a mouse model of polycystic ovary syndrome

For many women of childbearing age, the reproductive system is a complex, self-regulating machine that relies on a delicate balance of hormones to function. When this balance is disrupted, a condition known as polycystic ovary syndrome, or PCOS, can take hold. This is not merely a matter of irregular cycles; it is a metabolic and endocrine disorder where the ovaries produce too much testosterone, a male hormone, and fail to release eggs properly. Instead of maturing and releasing an egg, the follicles that should contain them often stall, turning into fluid-filled cysts that line the ovaries. This hormonal chaos frequently leads to weight gain, difficulty conceiving, and a higher risk of miscarriage, making the search for effective treatments a critical priority for medical science.

In a recent study conducted at Shiraz University of Medical Sciences, researchers set out to explore a new approach to fixing this broken machinery. They focused on two potential treatments: metformin, a common drug used to manage blood sugar and insulin resistance, and selenium nanoparticles, which are microscopic particles of the mineral selenium designed to be easily absorbed by the body. While metformin is a standard first-line treatment, it can cause digestive issues and does not work for everyone. Selenium, known for its ability to fight oxidative stress and inflammation, has shown promise in animal studies, but its potential when combined with metformin in a model of PCOS had not been fully explored. The researchers wanted to see if these two agents, working together, could repair the damage to the ovaries and improve the quality of eggs better than either could alone.

To investigate this, the team created a realistic model of the disease using sixty female mice. They induced PCOS by administering a substance called letrozole, which blocks the conversion of androgens into estrogen, mimicking the hormonal imbalance seen in humans. Over a period of thirty-six days, the mice were divided into groups: some received only the disease-inducing substance, some received metformin, some received the selenium nanoparticles, and some received both treatments together. The researchers then carefully measured how these interventions affected the animals' bodies, their hormone levels, and the microscopic structure of their ovaries. They used a specialized counting method to examine the ovaries under a microscope, looking at the size and number of follicles, the presence of cysts, and the health of the cells that nurture the developing eggs.

The results confirmed that the untreated mice with PCOS suffered from significant physical and hormonal distress. These animals gained more weight, had higher body mass indices, and their ovaries became enlarged and filled with cysts. Their blood showed elevated levels of testosterone, and their ovaries were packed with immature follicles that had failed to develop, while the number of healthy, mature eggs dropped sharply. The microscopic examination revealed that the protective layers of cells surrounding the eggs were thinning, and the eggs themselves were often misshapen or stuck in an immature state. This confirmed that the model successfully replicated the key features of the human condition, including the disruption of egg maturation and the accumulation of harmful cysts.

When the researchers introduced the treatments, the picture began to change. Both metformin and the selenium nanoparticles, when given individually, helped to reverse many of these negative effects. The animals treated with either drug gained less weight, and their testosterone levels dropped closer to normal ranges. More importantly, the structure of their ovaries improved. The number of cysts decreased, and the ovaries began to produce more healthy follicles. The eggs inside these follicles were larger and more likely to reach maturity. Notably, the combined administration of selenium nanoparticles and metformin substantially restored the ovarian architecture, reduced cyst formation, and preserved the integrity of granulosa cells, indicating a synergistic protective effect on ovarian morphology.

Beyond just the structure of the ovaries, the study looked closely at the quality of the eggs themselves. In the untreated PCOS group, the eggs often failed to expand their surrounding protective cells, a process necessary for successful fertilization, and many remained stuck in an early stage of development. The combination of selenium nanoparticles and metformin significantly improved this process. It helped the eggs reach the final stage of maturity, known as metaphase II, which is the state required for fertilization to occur. The eggs from the treatment groups were more likely to be perfectly formed, with fewer defects, and their surrounding cells expanded fully, creating a healthier environment for potential conception. The researchers found that this dual approach not only lowered the harmful hormones but also actively repaired the cellular machinery that allows an egg to mature and be released.

The study concludes that while both metformin and selenium nanoparticles offer therapeutic benefits for polycystic ovary syndrome, their combined use creates a superior outcome. By targeting both the metabolic imbalances and the oxidative stress that damage the ovaries, the two treatments work together to restore normal function. The findings suggest that this combination could be a promising strategy for improving fertility and ovarian health in PCOS, offering a path forward that goes beyond the limitations of current single-drug therapies. While these results are specific to a mouse model, they provide a strong foundation for understanding how these agents might interact to heal the reproductive system in more complex biological systems.